Home

Bringing LSPR Nanotechnology to POC and Mobile Diagnostics

LamdaGen’s L’AuRa digital platform enables diagnostic sensitivities and precise quantitation at levels far beyond the expected. The Company’s patented plasmonic technologies (LSPR nanotechnology) produces highly robust biosensors in the form of nanostructured metallic thin-films that exhibit remarkable optical detection capabilities.

The Company’s L’AuRa Point of Care (POC) diagnostic platform enables an important performance shift away from traditional central laboratory analog testing to a rapid decentralized digital one. The L’AuRa testing system delivers rapid quantitative results in small mobile formats at the point of clinical need.

Chart above illustrates L’AuRa’s diagnostic performance as compared to ELISA and Lateral Flow

Diagnostic multi-panel fluidic LSPR chip

Enabling ultra-sensitive, rapid and precisely quantitative POC and mobile diagnostics

Saliva-based Cortisol Assay: Read More ›

Troponin I (cTnI) Ap Note: Read More ›

L’AuRa Platform for Next-Generation Diagnostics: Read More ›

 

L’AuRa Digital Diagnostics

The L’AuRa diagnostic system is ideal for enabling high sensitivity, quantitative POC, mobile rapid testing.

Learn More ›

LightPath™ S4

LamdaGen’s LightPath S4 system performs highly sensitive label-free, real-time monitoring and characterization of biomolecular interactions.

Learn More ›

LSPR Biosensors

LamdaGen’s metallic thin-film LSPR-based Optical Biosensors for research and development in the areas of Life Science and Cleantech.

Learn More ›

News & Literature

LamdaGen Corporation Receives Notice of Allowance to Grant European Patent for Enzymatic Assays Performed on LSPR Based Plasmonic Nano-Sensors Read More ...

ACS Nano Publication: Cellular Functional Immunoanalysis Using LamdaGen LSPR Biosensors Read More ...

More News >